US 8288525
Compositions and methods for inhibiting expression of CD45 gene
granted A61PA61P25/00A61P31/12
Quick answer
US patent 8288525 (Compositions and methods for inhibiting expression of CD45 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Oct 16 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61P, A61P25/00, A61P31/12, A61P31/14, A61P31/16